この証券購入契約(以下「合意”) は2024年9月28日付で、デラウェア州法人であるプライムメディシン、インク。との間で締結されました(以下「会社”), and Bristol-Myers Squibb Company, a Delaware corporation (the “購入者”).
前文
A. The Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “証券法1933年(以下、「証券法」という)”), and Rule 506 of Regulation D (“それに加えて、本合意に基づき当事者は同時に、付属文Aに添付された登録権協定(以下、「「登録権協定」といいます)を締結する予定です。この協定に基づき、当社は、本合意に基づき発行された株式に関連する一定の登録権を投資家に提供します。詳細な条件については、当該協定に規定されています。米国証券取引委員会が制定した規則506(b)去除規則に基づく証券登録の免除を依拠としている委員会また、証券法の規制Dの506によって提供される証券登録の免除を頼りに、この加入を実行し提出しています。
購入者は、本契約に記載されている条件の下で、会社が0.00001ドルの普通株11,006,163株を購入し、会社が売却することを希望しています。普通株式」、会社の普通株共有$0.00001の価値、(それぞれ「シェアブライアン・パスカル氏(Reporting Person)株式”) for an aggregate purchase price of $55,000,000 (the “申込金額”).
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser hereby agree as follows:
第I章定義
1.1定義. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this 第1.1項
:
(vi)a certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Shares, (b) certifying the current versions of the certificate of incorporation, as amended, and by-laws of the Company and (c) certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company, in the form attached hereto as 展示品C;
(vii)the Compliance Certificate referred to in 本条項 5.1(i);
(viii)a certificate evidencing the formation and good standing of the Company issued by the Secretary of State (or comparable office) of the State of Delaware, as of a date within three (3) Business Days of the Closing Date;
(ix)a certificate evidencing the Company’s qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company is qualified to do business as a foreign corporation, as of a date within three (3) Business Days of the Closing Date; and
3.1会社の表明と保証. Except as disclosed in the SEC Reports [***], the Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date), to the Purchaser:
(a)組織と善行立場. The Company and each of its Subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a Material Adverse Effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the Subsidiaries listed in the SEC Reports.
(b)違反またはデフォルトはございません。親保証人またはその子会社は、以下の問題がございません:(i)規約、設立状況または同様の組織文書に違反すること、(ii)債務契約、抵当権、信託設定契約、貸付契約または親保証人またはその子会社が契約または拘束され、または親保証人またはその子会社の財産または資産が対象となる契約または記録に含まれるいかなる用語、契約条件または節の適切な履行または遵守においてデフォルトはありません。また(iii)裁判所または仲裁人、政府または規制当局の任意または規定された法律、条例、命令、規則に違反しておらず、個別にまたは全体的に、重大な悪影響(マテリアル・アドバース・エフェクト)を及ぼすものではありません。. Neither the Company nor any of its Subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any property or asset of the Company or any of its Subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.
(e)提出書類、同意および承認. Neither the Company nor any of its Subsidiaries is required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including the issuance of the Shares), other than (i) the filing with the Commission of one or more Registration Statements in accordance with the requirements hereof, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the Securities Act, if applicable, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with セクション4.4 of this Agreement, and (vi) those that have been made or obtained prior to the date of this Agreement (the “必要な承認”).
(f) 株の発行. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights and the holder of the Shares shall be entitled to all rights accorded to a holder of Common Stock. Assuming the accuracy of
the representations and warranties of the Purchaser in this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws.
(h)ストックオプション会社の株式ベースの報酬プランに基づき付与された株式オプション(以下「ストックオプション”) granted pursuant to the stock-based compensation plans of the Company and its Subsidiaries (the “Company Stock Plans”), (i) each Stock Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “コード”) so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the Board of Directors (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including the rules of the Principal Trading Market and any other exchange on which Company securities are traded, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their results of operations or prospects.
(s)サイバーセキュリティ会社とその子会社の情報技術資産および機器、コンピューター、システム、ネットワーク、ハードウェア、ソフトウェア、ウェブサイト、アプリケーション、およびデータベース(それぞれの従業員、サプライヤー、ベンダー、および会社またはその子会社によって管理または代理で保持されている第三者データを含む)は、現在行われている会社およびその子会社の事業の運営および提案されている事業の運営に必要なすべての点で適切で、適切に動作し、実行されており、会社の知識によると、すべてのバグ、エラー、欠陥、トロイの木馬、タイムボム、マルウェアおよびその他の不正プログラムから自由であると分かっていますITシステム”悪意のあるデータを含むバグ、エラー、欠陥、トロイの木馬、タイムボム、マルウェアなど全てからデータは無料でクリーンであることバグ”), except where such Bugs would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries implement and maintain, and have implemented and maintained, commercially reasonable controls, policies, procedures, and safeguards as are generally maintained by similarly situated companies (and which are consistent with industry standard practices) and which the Company and its Subsidiaries believe are reasonably adequate to protect their material confidential information and the integrity, continuous operation, redundancy and security of all It Systems and data (including all personally identifiable, sensitive or confidential data and all information subject to regulation under applicable Data Security Obligations (as such term is defined below)) (“個人情報”) collected, used or otherwise processed in connection with their businesses. Without limiting the foregoing, the Company and its Subsidiaries have used commercially reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, reasonable information technology, information security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans as are generally maintained by similarly situated companies (and which are consistent with industry standard practices) that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any It System or Personal Information used in connection with the operation of the Company’s and its Subsidiaries’ respective businesses (“侵害”). To the Company’s Knowledge, there has been no such Breach. The Company and its Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any such Breach.
(t)プライバシー. The Company and its Subsidiaries have complied and are in compliance with all published privacy policies and written notices, contractual obligations, industry standards that are contractually binding upon the company and its Subsidiaries, applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations in each case, regarding the collection, use, transfer, import, export, storage, protection, disposal, disclosure and other processing by or on behalf of the Company and its Subsidiaries of personally identifiable, sensitive, confidential or regulated data (“データセキュリティ義務”), except where the violation of or failure to comply with such Data Security Obligations would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received any notification of or complaint regarding, or are otherwise aware of any other facts that, individually or in the aggregate, would reasonably indicate, non-compliance
with any Data Security Obligation or has any knowledge of any event or conditions that would reasonably be expected to result in any such non-compliance, and there is no action, suit, investigation or proceeding by or before any court or governmental agency, authority or body pending or, to the Company’s Knowledge, threatened alleging non-compliance by the Company or any of its Subsidiaries with any Data Security Obligation. The Company and its Subsidiaries have at all times taken steps reasonably necessary in accordance with industry standard practices (including, without limitation, implementing and monitoring compliance with adequate measures with respect to technical and physical security) to protect its It Systems and Personal Information against a Breach, except in each case to the extent that the failure to do so would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect.
(x) サーバンズ・オクスリー法. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley法”), including Section 402 related to loans and Sections 302 and 906 related to certifications.
(y)Certain Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or the Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company with respect to the offer and sale of the Shares. The Purchaser shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type
contemplated in this Section 3.1(y) 取引書に明示されている取引に関連して発生する可能性があるものに関連して生じたいかなる損害、損失または費用(手数料や実費を含む)について、会社は買収者を保護し、賠償し、無害にするものとする。
「時価」とは、5.3条に従い決定される株式の時価を意味します。当社は、1933年投資会社法及び証券取引委員会の規則及び規定(以下「1933年投資会社法」)に従うことを求められていない投資会社であるか、又はそれらの法規上で「投資会社」または「投資会社により管理される」実体であることを示しておらず、かつ、取引のオファリング及び売却、それに伴う利益の使用方法に関して、Registration Statement、Time of Sale Information及びプロスペクタスに記載されている内容に沿っていることになります。 会社は、修正された1940年投資会社法の意味において、「投資会社」であることも、ならず、またはならない。株式の支払いを受領した直後、会社は1950年投資会社法の適用を受けるようにならないように事業を運営しなければなりません。
(ab)登録権限. Other than the Purchaser pursuant to セクション4.13 hereof, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company other than those securities which are currently registered on an effective registration statement on file with the Commission that have not been duly waived or satisfied.
(親会社)リスティングとメンテナンスの要件. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the twelve (12) months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all listing and maintenance requirements of the Principal Trading Market on the date hereof.
(aj)はコードのセクション409Aを意味します。反マネーロンダリング法の遵守会社およびその子会社の運営は、財務記録および報告義務を遵守し、Currency and Foreign Transactions Reporting Act of 1970のような関連法規に常に準拠しており、銀行秘密法、2001年「アメリカ合衆国愛国者法」の第III章改正による銀行秘密法、会社またはその子会社が事業を行うすべての管轄区域の適用される資金洗浄法、関連する規則およびそれに関連するまたは同等の規則、規制または政府機関によって発行され、管理され、施行されるガイドラインなど(総称して「反マネーロンダリング法」)およびアンチマネーロンダリング法に関する会社またはその子会社による訴訟、行政機関、権限、仲裁人による訴訟、訴訟または手続きは現在進行中でなく、会社の了解によるとも脅かされていません。
(ak)制裁法との衝突はありません」)米国政府(米国財務省の外国資産管理局(「OFAC”) or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person”), the
United Nations Security Council (“UNSC”), the European Union, His Majesty’s Treasury (“HMT”) or other relevant sanctions authority (collectively, “制裁会社またはその子会社、取締役、役員、従業員、または会社またはその子会社に関連する個人または法人、または1人以上の個人または法人によって管理されていることを、またはこれらのいずれかの国または地域に所在し、組織されているか、または居住していることはありません、その国または地域が制裁の対象または標的となっている国または地域である、いわゆるドネツク人民共和国、いわゆるルガンスク人民共和国、ウクライナのザポリージャ、フェルソン、クリミア地域、および執行命令14065号に基づいて識別されたウクライナの他の対象地域、キューバ、イラン、北朝鮮、シリア(以下、「対象地域」という)。制裁を受けている国会社は、ここでの株式の調達の利益を直接的にも間接的にも使用せず、資金提供または他の方法でそのような利益を子会社、合弁事業パートナー、または他の個人または法人に提供せず(i)その資金提供または促進当時制裁の対象となっている個人または企業との取引またはビジネスを資金提供または促進するため、(ii)制裁の対象地域での取引またはビジネスを資金提供または促進するため、または(iii)制裁の違反をもたらすその他の方法で、取引に参加する者(主幹、顧問、投資家など)による違反を結果とする。<br>5年間にわたり、会社およびその子会社は、故意に従事しておらず、現在も知らないまま従事しておらず、制裁の対象または標的となっている個人との取引または関係、または制裁対象国との取引または取引を行っていません。
(青)規制事項;製品及び製品候補. The Company (collectively with its Subsidiaries): (i) has operated and currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws (as defined below) of the Food and Drug Administration (“FDA”), the Department of Health and Human Services and any applicable comparable foreign or other regulatory authority (collectively, the “Applicable Regulatory Authorities”) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company’s or its subsidiary’s product candidates manufactured or distributed by the Company; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (A) any Health Care Laws or (B) any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (“Regulatory Authorizations”); (iii) possesses all material Regulatory Authorizations required to conduct its business as currently conducted, and such Regulatory Authorizations are valid and in full force and effect in all material respects and, to the Company’s Knowledge, the
Company is not in material violation of any term of any such Regulatory Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Applicable Regulatory Authorities or any other third party alleging that any product candidate of the Company is in violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and (viii) has not (and to the Company’s Knowledge, none of its employees, officers and directors, or agents has) been excluded, suspended or debarred from participation in any government health care program or human clinical research and, to the Company’s Knowledge, neither the Company nor any of its employees, officers or directors or agents is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
3.2買受人の表明と保証. The Purchaser hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows:
(a)組織能力;権限. The Purchaser is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Purchaser and performance by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the Purchaser. Each Transaction document to which the Purchaser is a party has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application.
(b)利益相反行為の禁止. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Purchaser, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Purchaser is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree of any court or arbitrator or governmental or regulatory authority applicable to the Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Purchaser to perform its obligations hereunder.
(c) 伝説の削除設定されている伝説 4.1(b)に従ってキャンセルまたは変換される有効時間の直前に発行および未発行となった株を除いたシェア above shall be removed and the Company shall, or shall cause its Transfer Agent to, as applicable, issue book entry statements without such legend or any other legend to the holder of the applicable Shares upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account at the Depository Trust Company (“DTC”), if (i) such Shares sold or transferred pursuant to (x) the plan of distribution set forth in an effective registration statement registering the Shares for resale (during such time that such registration statement is effective and not withdrawn or suspended) or (y) Rule 144, in each case upon delivery by the Purchaser to the Company, the Transfer Agent, as applicable, and Company Counsel of a customary seller’s representation letter and broker’s representation letter confirming the transfer of such Shares in the manner described in this clause (i), together with any other documentation reasonably required by the Transfer Agent and/or the Depository Trust Company (the “Resale Deliverables”), or (ii) in the absence of any sale of the Shares, following the date that is the one-year anniversary of the Closing Date and if requested by the Purchaser in writing, if such Shares are eligible for sale under Rule 144, without compliance with any of the requirements of such rule, including the current public information requirement and without volume or manner-of-sale restrictions, upon delivery by the Purchaser to the Company, the Transfer Agent, as applicable, and
Company Counsel of a customary representation letter from the Purchaser confirming that the requirements set forth in this clause (ii) have been satisfied, together with any other documentation reasonably required by the Transfer Agent and/or the Depository Trust Company (the “Non-Resale Deliverablesこのような意見の提示または前項に基づくその記号の除去に関連する料金(移転代理人、会社の法律顧問、その他何らかの事項を含む)は、会社が負担します。会社は、この記号の除去に係る譲渡の制限を拡大することを示す、記録への記載または移転代理人への指示を行ってはなりません。 Section 4.1(c)ここでの記号の除去が必要となる株式に関する電子証明書は、移転代理人によって、購入者が指示した通りにDTCを通じて購入者の主要ブローカーの口座に入金される可能性があります。
(d) FASTコンプライアンス会社は、その譲渡代理人およびその後の譲渡代理人に対し、以下の形式の不可撤告の指示を発行しなければなりません。 展示品B 」という)FASTコンプライアンス”). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this セクション4.1(d)に従って (or instructions that are consistent therewith) will be given by the Company to its transfer agent in connection with this Agreement.
(e) 謝辞. The Purchaser acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Shares or any interest therein without complying with the requirements of the Securities Act. While the Registration Statement remains effective, the Purchaser hereunder may sell the Shares in accordance with the plan of distribution contained in the Registration Statement and if it does so it will comply therewith and with the related prospectus delivery requirements unless an exemption therefrom is available. The Purchaser agrees that if it is notified by the Company in writing at any time that the Registration Statement registering the resale of the Shares is not effective or that the prospectus included in such Registration Statement no longer complies with the requirements of Section 10 of the Securities Act, the Purchaser will refrain from selling such Shares until such time as the Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant with Section 10 of the Securities Act, unless the Purchaser is able to, and does, sell such Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act. Both the Company and its Transfer Agent, and their respective directors, officers, employees and agents, may rely on this この合意におけるセクション4.1(e) and the Purchaser hereunder will indemnify and hold harmless each of such persons from any breaches or violations of this セクション4.1(e).
4.4証券法の開示;宣伝ニューヨーク市時間午前9時までに、2番目(2)nd) Trading Day immediately following the date hereof, the Company shall issue a press release (the “プレスリリース”) reasonably acceptable to the Purchaser disclosing all material terms of the transactions contemplated hereby. On or before 9:00 A.m., New York City time, on the second (2nd) Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-k with the Commission describing the terms of the Transaction Documents (and such Current Report on Form 8-k or subsequent report on Form 10-Q shall include as exhibits the material Transaction Documents (including, without limitation, this Agreement)). Notwithstanding the
foregoing, the Company shall not publicly disclose the name of the Purchaser or an Affiliate of the Purchaser, or include the name of the Purchaser or an Affiliate of the Purchaser in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, such consent not to be unreasonably withheld, except (i) as required by federal securities law in connection with (A) any registration statement contemplated by セクション4.13 hereto and (B) the filing of final Transaction Documents (including signature pages thereto) with the Commission and (ii) to the extent such disclosure is required by law, request of the Staff of the Commission or Trading Market regulations, in which case the Company shall provide the Purchaser with prior written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received from the Company, any Subsidiary or any of their respective officers, directors, employees or agents, that is not disclosed in the Press Release unless the Purchaser shall have executed a written agreement regarding the confidentiality and use of such information.
4.12日付後のショートセールおよび機密保持買い手は、この契約の取引が最初に公表されるか、またはこの契約が完全に終了するまで直接または間接的に、会社の証券(会社の証券に係るショートセールを含む)に関与しないであろうし、取引関係者にも同様にさせないことを請け負います。 セクション4.4 もしくは、本契約が完全に終了するまで セクション6.17買手は、本契約によって予定されている取引が会社により公開開示されるまで、本取引および取引書類および開示スケジュールに含まれる情報の存在と条件の機密保持を確約する セクション4.4前項にかかわらず、本取引のロックアップ期間の満了後に、買手が会社の有価証券に対する空売りを行わないことを表明、保証、契約するものではない セクション 4.16; provided, however買手は、決済日を開始日とし、(x)初回の登録声明の有効な登録日、(y)決済日から24か月記念日、または(z)買手が株式を保有していなくなる日のうちいずれか早いものまで、ネット空売り(以下定義)を行わないことに同意するが、本ロックアップ期間の満了前であっても承諾されない セクション4.16. For purposes of this セクション4.12, a “Net Short Sale” by the Purchaser shall mean a sale of Common Stock by the Purchaser that is marked as a short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by the Purchaser. Notwithstanding the foregoing, in the event that the Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of the Purchaser's assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio
manager that have knowledge about the financing transaction contemplated by this Agreement. Moreover, notwithstanding the foregoing, in the event that a Purchaser has sold Shares pursuant to Rule 144 prior to the Effective Registration Date of the initial Registration Statement and the Company has failed to deliver certificates without legends prior to the settlement date for such sale (assuming that such certificates meet the requirements set forth in Section 4.1(c) for the removal of legends), the provisions of this セクション4.12 購入者が株式の納品を目的としてネットショートセールに参加することを禁止しないこと。 購入者は、委員会が現在、再販売登録声明の効力発生前に確立された空売りポジションを当該登録声明に含まれる株式でカバーすることは、証券法第5条の違反となるとの立場を取っていることを理解し認識する。情報65項目、公開電話解釈のマニュアル(A Office of Chief Counsel, Division of Corporation Financeにより編集された1997年7月のもの)のSection 5のSection Aに記載されている。
(b)効力発生期限株式会社は、登録声明をファイリングした後、できるだけ迅速に効力を生じるように商業的に合理的な努力を行います(「効力生じる日」)そしていかなる場合においても、米国証券取引委員会(「スタッフ」)の職員が電子メールまたは電話で、登録声明に対する審査を行わないことまたは追加のコメントがないことを示す日から五(5)営業日以内であり、90th) day after the Closing Date (or the one hundred twentieth (120th) day if the Commission reviews such Registration Statement) (such date, the “効力発生期限”).
(c)The Company shall promptly prepare and file with the Commission such amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earliest of (i) the third (3rd) anniversary of the Effective Registration Date of the Registration Statement, (ii) such time as all of the Shares purchased by the Purchaser pursuant to the terms of this Agreement have been sold pursuant to the Registration Statement, or (iii) such time as the Shares become eligible for resale by non-affiliates without any volume limitations or other restrictions pursuant to Rule 144 under the Securities Act (including, for the avoidance of doubt, Rule 144(i)(2)) or any other rule of similar effect (the “有効期間”).
(d)もし(i)登録声明書が提出期限までに委員会に提出されずに提出期限を違反している場合(
セクション4.13(a) (a “ファイリング違反または(B)委員会によって効力発生期限までに有効と宣言されていない場合(「
「有効化失敗」とは」)、または(ii)効力期間中の任意の日および登録声明書が効力を持つと宣言された日以降、該当の登録声明書に含める必要がある株式のすべての売り出しが行われない場合(ブラックアウト期間中以外)、当該登録声明書を効力を持たせ続けられない、売り出しが行われるために必要な情報を明らかにしない、この契約で必要とされる十分な株式数を登録しないなどの理由で、または(iii)提出期限後、そして登録声明書が有効でないか売却できる状態にない場合、会社が「
」」、または15(d)条に基づく規定上、適切な報告を委員会に提出しないために、Rule 144(c)(1)に違反しており、その結果として、会社の関係会社でない取得者がRule 144の下で制限なく株式を売ることができない」メンテナンスの失敗”), then, in satisfaction of the damages to the Purchaser by reason of any such delay in or reduction of its ability to sell the Shares, the Company shall pay to the Purchaser then holding Shares relating to such Registration Statement an amount in cash equal to 1.0% of the Purchase Price for the Shares then held by the Purchaser on each of the following dates (as applicable): (x) on every thirtieth (30th) day (prorated for periods totaling less than 30 days) following such Filing Failure until such Filing Failure is cured; (y) on every thirtieth (30th) day (prorated for periods totaling less than 30 days) following such Effectiveness Failure until such Effectiveness Failure is cured; and (z) on every thirtieth (30th) day (prorated for periods totaling less than 30 days) following such Maintenance Failure until such Maintenance Failure is cured. The payments to which the Purchaser shall be entitled pursuant to this セクション 4.13(d) そのような遅延や制約によるセキュリティの売却能力の遅延により、購入者に、購入金額の1%相当の金額を現金で支払うこととされ、これは罰則ではなく、部分的な準備資金として支払われます。「登録遅延支払い」は、(I)上記の日付、および(II)登録遅延支払いの要因または失敗の発生後3営業日のいずれか早い日に支払われます。会社が適時に登録遅延支払いを行わない場合、その登録遅延支払いは、全額支払われるまで毎月1.5%(部分月間の場合は按分)の利率で利息が発生します。”; ただし、有効期間の終了後に登録遅延支払いが必要となる場合はありません。さらに、このセクション 4.13(d)に基づく累計登録遅延支払いは、購入者が保有する株式価格の6%を超えてはなりません(つまり、総遅延が6ヶ月に相当する)。登録遅延支払いは、(I)そのような登録遅延支払いが生じたカレンダー月の最終日、および(II)その登録遅延支払いが生じた事件または違反が解消された後の3営業日のいずれか早い方に支払われます。登録声明の提出期限および有効期限は、購入者が同意書の要請に対して不遅滞で情報を提供しなかったことが原因で遅れた場合に、税法の要件に従って登録声明を完了するために会社が提出または有効期限を取得できなかった場合に、標準または損害なしで延長されます。明確にするために、株式が証券法のRule 144(b)(1)(i)およびRule 144(i)(2)に基づき、ボリューム制限やその他の制限なしで再販売可能になる時点を指します。 セクション 4.13(d) 購入者が保有する株式の購入価格の6%を超える登録遅延支払いは入りません。すなわち、総遅延期間が6ヶ月に相当します。登録遅延支払いは、該当する登録遅延支払いが発生したカレンダー月の最終日、またはその登録遅延支払いの原因となる出来事または違反が解消された後の3営業日の早い方、のいずれかに支払われます。rdここで、株式が証券法のRule 144(b)(1)(i)およびRule 144(i)(2)に基づき、ボリューム制限やその他の制限なしで再販売可能になる時点を指します。
(e)関連する義務. At such time as the Company is obligated to file the Registration Statement with the Commission pursuant to セクション4.13(a), the Company will use commercially reasonable efforts to effect the registration of the Shares in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:
(i)The Company shall submit to the Commission, within three (3) Business Days after the Company learns that no review of the Registration Statement will be made by the Staff or that the Staff has no further comments on the Registration Statement, as the case may be, a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) Business Days after the submission of such request, subject to the approval of the Staff. The Company shall keep each Registration Statement effective pursuant to Rule 415 at all times with respect to the Purchaser’s Shares until the expiration of the Effectiveness Period. The Company shall ensure that each Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in which they were made) not misleading. Notwithstanding the registration obligations set forth in this セクション6, in the event the Commission informs the Company that all of the Shares cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (A) inform each of the holders thereof and use its commercially reasonable efforts to file amendments to the Registration Statement as required by the Commission and/or (B) withdraw the Registration Statement and file a new registration statement (a “新規登録声明”), in either case covering the maximum number of Shares permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Shares as a secondary offering; provided, however, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the Commission for the registration of all of the Shares in accordance with the SEC Guidance, including without limitation, the Manual of Publicly Available Telephone Interpretations D.29. Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages in Section 4.13(d), if any SEC Guidance sets forth a limitation of the number of Shares permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Shares), unless otherwise
directed in writing by the Purchaser as to its Shares, the number of Shares to be registered on such Registration Statement will first be reduced by Shares not acquired pursuant to the Purchase Agreement (whether pursuant to registration rights or otherwise) and second by Shares (applied, in the case that some Shares may be registered, to the Purchaser on a pro rata basis based on the total number of unregistered Shares held by the Purchaser, subject to a determination by the Commission that the Purchaser must be reduced first based on the number of Shares held by the Purchaser). In the event the Company amends the Registration Statement or files a New Registration Statement, as the case may be, under clauses (A) or (B) above, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of Shares in general, one or more registration statements on Form S-3 or such other form available to register for resale those Shares that were not registered for resale on the Registration Statement, as amended, or the New Registration Statement (the “。会社が初期登録声明を修正したり新規登録声明を申請する場合、前述の(i)または(ii)の条件に従って、初期登録声明の修正版または新規登録声明に登録されていない登録可能な株式について、委員会の決定に基づき、委員会が許可する限りまたは会社または一般の有価証券の登録者に提供されたSECガイダンスに従って、S-3フォームまたはその他の利用可能なフォームで1つ以上の登録声明を提出する商業的に合理的な努力を行う”).
(f)ブラックアウト期間. Notwithstanding the foregoing obligations, the Company may, upon written notice to the Purchaser, which notice shall not contain any information that is or the Company reasonably believes is material non-public information, for a reasonable period of time after effectiveness, not to exceed 30 days (each, a “ブラックアウト期間”), delay the filing of an amendment to a Registration Statement or suspend the effectiveness or use of any Registration Statement, in the event that (i) negotiation or consummation of a transaction by the Company is pending or an event has occurred, which negotiation, consummation or event, the Board of Directors reasonably believes, upon the advice of legal counsel, would require additional disclosure by the Company in the Registration Statement of material information that the Company has a bona fide business purpose for preserving as confidential and the non-disclosure of which in the Registration Statement would be expected, in the reasonable determination of the Board of Directors, upon the advice of legal counsel, to cause the Registration Statement to fail to comply with applicable disclosure requirements, or (ii) an event occurs that makes any statement of a material fact made in such Registration Statement, including any document incorporated by reference therein, untrue or that requires the making of any additions or changes in the Registration Statement in order to make the statements therein not misleading; provided, however, that any Blackout Period shall terminate upon the earlier of (A) the expiration of such 30-day period or (B) the completion, resolution or public announcement of the relevant
transaction or event. If the Company suspends the effectiveness of a Registration Statement pursuant to this Section 4.13(f), the Company shall (x) as promptly as reasonably practicable following the termination of the circumstance which entitled the Company to do so, take such actions as may be necessary to reinstate the effectiveness of such Registration Statement and give written notice to the Purchaser authorizing the Purchaser to resume offerings and sales pursuant to such Registration Statement, and (y) cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of the Purchaser in accordance with the terms of this Agreement in connection with any sale of Shares with respect to which the Purchaser has entered into a contract for sale, and delivered a copy of the prospectus included as part of the applicable Registration Statement (unless an exemption from such prospectus delivery requirement exists), prior to the Purchaser’s receipt of the notice of a Blackout Period and for which the Purchaser has not yet settled. If, as a result thereof, the prospectus included in such Registration Statement has been amended or supplemented to comply with the requirements of the Securities Act, the Company shall enclose such revised prospectus with the notice to Purchaser given pursuant to this 11会社は、この規定に基づく権利を行使する権利を有する。 セクション4.13(f) 12か月間の期間について60日を超えないように、本項のすべてのブラックアウト期間の合計日数が60日を超えないようにすることができる。いずれのブラックアウト期間も満了した後、購入者からのさらなる要求なしに、会社は登録声明書の提出(必要に応じて修正または補足も)または、購入者がここで設定されたように株式を再販売できるように他の文書を提出することを行う。
4.15弁償本条項の目的について セクション4.15: (i) the term “Purchaser/Affiliate” shall mean any Affiliate of and investment adviser to the Purchaser, and the members, the directors, officers, partners, employees, members, managers, agents, representatives and advisors of the Purchaser and each Person, if any, who controls the Purchaser within the meaning of the Section 15 of the Securities Act or Section 20 of the Exchange Act; and (ii) the term “登録声明書” shall include any preliminary prospectus, final prospectus (the “目論見書”), free writing prospectus, exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement referred to in セクション4.13.
(b)The Purchaser will indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement, agents, and employees and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages, liabilities or expenses that the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of the Purchaser) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i) any failure to comply with the covenants and agreements contained in 第6.14項 hereof respecting the sale of the Shares or (ii) any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Purchaser or any Purchaser/Affiliate expressly for use therein; and will reimburse the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person for any legal and other expense reasonably incurred by the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person in connection with investigating, defending, settling, compromising or paying any
(c)この後すぐに、この保護された当事者による通知の受領後 セクション4.15 ただし、(a)本取引に基づくPurchaserの累積責任の総額は、Purchaserが株の売却によって受け取った純売上高を超えないものとし、(b)Purchaserは、Purchaserの書面による同意なしに決着がなされた場合のいかなる損失、請求、損害、責任または訴訟についても責任を負わないこと セクション4.15 ただし、(a)本取引に基づくPurchaserの累積責任の総額は、Purchaserが株の売却によって受け取った純売上高を超えないものとし、(b)Purchaserは、Purchaserの書面による同意なしに決着がなされた場合のいかなる損失、請求、損害、責任または訴訟についても責任を負わないこと セクション4.15 to the extent it is not prejudiced as a result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it may wish, jointly with all other indemnifying parties similarly notified, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party, and the indemnifying party and the indemnified party shall have reasonably concluded, based on an opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of its election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this セクション4.15 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed such counsel in connection with the assumption of legal defenses in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying party, representing all of the indemnified parties who are parties to such action) or (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of action, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying party. In no event shall any indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have approved in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding.
(d)If the indemnification provided for in this セクション4.15 is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c) of this セクション4.15 in respect to any losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Purchaser from the private placement of Shares hereunder or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but the relative fault of the Company and the Purchaser in connection with the statements or omissions or inaccuracies in the representations and warranties in this Agreement and/or the Registration Statement that resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Purchaser on the other shall be deemed to be in the same proportion as the amount paid by the Purchaser to the Company pursuant to this Agreement for the Shares purchased by the Purchaser that were sold pursuant to the Registration Statement bears to the difference (the
“差異”) between the amount the Purchaser paid for the Shares that were sold pursuant to the Registration Statement and the amount received by the Purchaser from such sale. The relative fault of the Company on the one hand and the Purchaser on the other shall be determined by reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the Company or by the Purchaser and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c) of this セクション4.15, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in paragraph (c) of this セクション4.15 with respect to the notice of the threat or commencement of any threat or action shall apply if a claim for contribution is to be made under this paragraph (d); provided, however, that no additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c) for purposes of indemnification. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this セクション4.15 were determined solely by pro rata allocation (even if the Purchaser were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this セクション4.15, the Purchaser shall not be required to contribute any amount in excess of the amount by which the Difference exceeds the amount of any damages that the Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
4.16Lock-Up期間.
(a)The Purchaser agrees that, for a period (the “ロックアップ期間”) until the first to occur of either (i) [***], or (ii) the third (3rd) anniversary of the Effective Date (as defined in the Collaboration Agreement), the Purchaser will not, without the prior written consent of the Company, directly or indirectly, (1) offer, sell, contract to sell, pledge, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of the Common Stock, or any securities convertible into or exercisable or exchangeable for the Common Stock (including, without limitation, shares of Common Stock or any such securities which may be deemed to be beneficially owned by the Purchaser in accordance with the rules and regulations promulgated under the Securities Act, as the same may be amended or supplemented from time to time (such shares or securities, the “Beneficially Owned Shares”)); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Beneficially Owned Shares, Common Stock, or any securities convertible into or exchangeable for the Common Stock, regardless of whether any such transaction described herein is to be settled by delivery of the Common Stock or such other securities, or by delivery of cash or otherwise; (3) make any demand for, or exercise any right with respect to, the registration of any shares of the Beneficially Owned Shares, Common Stock or any security convertible into or exercisable of exchangeable for the Common Stock; or (4) publicly announce any intention to do any of the foregoing. Notwithstanding the foregoing, the restrictions set forth in clause (1) and (2) herein shall not apply to (a) transfers (i) as a bona fide gift or gifts, 提供 that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein, (ii) to any trust for the direct or indirect benefit of the Purchaser, 提供 信託の受託者がここで規定された制限に書面で従うことに同意すること、およびそのような移転が価値の譲渡を伴わず、すべてのオフィサーおよび取締役が同じ制限を受け、そして同一株主が会社の発行済普通株式の1%以上(全ての発行済Preferred Stockを普通株式に換算したのち)を保有している場合にのみHolderに適用される。当該登録に関連するアンダーライターは、この内容を直接の第三者として受益することを意図しています。 提供 さらなる そのような譲渡が価値の譲渡を伴わない限り、事前に会社の書面による同意が必要であり、会社または普通株式に関与する事業結合、合併、企業結合、優先的引受け、交換オファーまたは類似する取引を行う(または普通株式を取得する取引)せず、普通株式、または共に普通株式とする株式、または普通株式に交換できる、権利付き証券を取得または行使する(または清算価値の証券を購入するオプションまたはウォレントを取得または行使する)こと、これによって行使される権利は「物理的」行使をファイナンスするために、その行使の一部を売却することを含む 提供 そのようなオプションまたはウォレントの行使によって発行される株式(または共に普通株式とする株式に換えられる、行使または交換可能な証券)も引き続き本契約の該当規定の対象となるべき セクション4.16本テキストに記載されている制限のいずれも、この セクション4.16 本取引において取得した普通株式には適用されません。また、取得者は普通株式または有益所有株式を自社の株主に分配することができます; 提供しかしながら、それぞれの場合において、そのような譲渡を行う前に、各譲受人は本 セクション4.16 期間中、